We are advancing novel antigen modulation technology that controls T cells to guide the immune system.
Greywolf Therapeutics has raised $50.0M in total funding. The most recent round was Series B. The last funding was announced in May 2024.
Greywolf Therapeutics's investors include Earlybird Venture Capital, Intermediate Capital Group, Oxford Science Enterprises, Canaan Partners, Andera Partners.
Greywolf Therapeutics is headquartered in Abingdon, United Kingdom.
We are advancing novel antigen modulation technology that controls T cells to guide the immune system.
Greywolf Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Greywolf Therapeutics — Funding & Investors." VCBacked, May 23, 2024, https://www.vcbacked.co/company/greywolf-therapeutics. Accessed September 14, 2026.
VCBacked. (2024). Greywolf Therapeutics — Funding & Investors. Retrieved September 14, 2026, from https://www.vcbacked.co/company/greywolf-therapeutics
{{cite web |title=Greywolf Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/greywolf-therapeutics |website=VCBacked |access-date=September 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated